Hill R J, Oleynek J J, Magee W, Knight D R, Tracey W R
Department of Cardiovascular & Metabolic Diseases, Central Research Division, Pfizer Inc., Groton, CT 06340, USA.
J Mol Cell Cardiol. 1998 Mar;30(3):579-85. doi: 10.1006/jmcc.1997.0621.
Although ischemic preconditioning (IP) in several species can be pharmacologically mimicked by selective adenosine A1 or A3 receptor agonists, it is currently unclear which receptor subtype (A1 and/or A3) is physiologically involved in mediating IP. To investigate this question, we determined (a) the affinity of adenosine for rabbit adenosine A1 and A3 receptors, and (b) the effects of selective rabbit A1 receptor blockade on IP and adenosine-mediated cardioprotection in a rabbit Langendorff model of myocardial ischemia-reperfusion injury. Adenosine was 19-fold selective for inhibition of N6-(4-amino-3-[125I]iodobenzyl)adenosine (125I-ABA) binding to recombinant rabbit A1 v rabbit A3 receptors (A1 Ki: 28 nm; A3 Ki 532 nm). Buffer-perfused rabbit hearts were exposed to 30 min regional ischemia and 120 min of reperfusion, and infarct size was measured by tetrazolium staining and normalized for area-at-risk (IA/AAR). Ischemic preconditioning (5 min global ischemia and 10 min reperfusion) or adenosine (20 micro M, 5 min) perfusion reduced infarct size (IA/AAR) to 17+/-3 and 14+/-2%, respectively (controls: 59+/-2%). Ischemic preconditioning and adenosine-mediated cardioprotection were completely blocked (57+/-2 and 61+/-4% IA/AAR, respectively) in the presence of a rabbit A1-selective concentration (50 nm) of the antagonist BWA1433 (rabbit A1 Ki: 3 nm; A3 Ki; 746 n m). Thus, whereas recent studies have demonstrated that selective A1 or A3 receptor agonists can both pharmacologically mimic IP, the results of the present study suggest that the adenosine-mediated component of IP in the isolated rabbit heart is preferentially mediated by adenosine A1 receptors, potentially due to adenosine's selectivity for this receptor subtype.
尽管在多个物种中,缺血预处理(IP)可通过选择性腺苷A1或A3受体激动剂在药理学上模拟,但目前尚不清楚在生理上介导IP的是哪种受体亚型(A1和/或A3)。为了研究这个问题,我们测定了:(a)腺苷对兔腺苷A1和A3受体的亲和力;(b)在兔心肌缺血-再灌注损伤的Langendorff模型中,选择性兔A1受体阻断对IP和腺苷介导的心脏保护作用的影响。腺苷对抑制N6-(4-氨基-3-[125I]碘苄基)腺苷(125I-ABA)与重组兔A1和兔A3受体结合具有19倍的选择性(A1的Ki:28 nM;A3的Ki:532 nM)。用缓冲液灌注的兔心脏经历30分钟的局部缺血和120分钟的再灌注,通过四氮唑染色测量梗死面积,并将其标准化为危险区域面积(IA/AAR)。缺血预处理(5分钟全心缺血和10分钟再灌注)或腺苷(20 μM,5分钟)灌注分别将梗死面积(IA/AAR)降低至17±3%和14±2%(对照组:59±2%)。在存在兔A1选择性浓度(50 nM)的拮抗剂BWA1433的情况下(兔A1的Ki:3 nM;A3的Ki:746 nM),缺血预处理和腺苷介导的心脏保护作用被完全阻断(分别为57±2%和61±4% IA/AAR)。因此,尽管最近的研究表明选择性A1或A3受体激动剂都可以在药理学上模拟IP,但本研究结果表明,在离体兔心脏中,IP的腺苷介导成分优先由腺苷A1受体介导,这可能是由于腺苷对该受体亚型的选择性。